TTM
−$1.32B
YoY change
+85.1%
5Y CAGR
—
Peak year (2017)
−$29.84M
Cumulative EBITDA
−$3.19B
EBITDA history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: −$1.09B
EBITDA growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: +85.1%
EBITDA history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | −$1.09B | +85.1% | −$501.49M | ||
| 2024 | −$589.02M | +36.9% | −$158.74M | ||
| 2023 | −$430.28M | +79.7% | −$190.81M | ||
| 2022 | −$239.47M | +33.2% | −$59.72M | ||
| 2021 | −$179.75M | +76.4% | −$77.83M | ||
| 2020 | −$101.91M | +109.7% | −$53.33M | ||
| 2019 | −$48.59M | +21.7% | −$8.68M | ||
| 2018 | −$39.91M | +33.8% | −$10.07M | ||
| 2017 | −$29.84M | — | — |
- 2025−$1.09B+85.1%
- 2024−$589.02M+36.9%
- 2023−$430.28M+79.7%
- 2022−$239.47M+33.2%
- 2021−$179.75M+76.4%
- 2020−$101.91M+109.7%
- 2019−$48.59M+21.7%
- 2018−$39.91M+33.8%
- 2017−$29.84M—
EBITDA values are taken from Revolution Medicines's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Revolution Medicines (RVMD)
According to Revolution Medicines's latest reported financial statements, the company's current EBITDA (TTM) is −$1.32B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Revolution Medicines (RVMD) most recent annual EBITDA stands at −$1.09B (2025) – surged 85.1% year-over-year.
2017 marks the peak EBITDA at −$29.84M, with the historical low of −$1.09B recorded in 2025.
Revolution Medicines EBITDA by Year
Revolution Medicines EBITDA 2025: −$1.09B
Revolution Medicines EBITDA in 2025 was −$1.09B, surged 85.1% from 2024. This figure represents the lowest annual value in the available history.
Revolution Medicines EBITDA 2024: −$589.02M
2024's EBITDA for Revolution Medicines came in at −$589.02M, surged 36.9% from 2023.
Revolution Medicines EBITDA 2023: −$430.28M
Revolution Medicines posted EBITDA of −$430.28M in 2023, surged 79.7% from 2022.
Revolution Medicines EBITDA 2022: −$239.47M
In 2022, Revolution Medicines reported EBITDA of −$239.47M, surged 33.2% from 2021.
Revolution Medicines EBITDA 2021: −$179.75M
Revolution Medicines EBITDA in 2021 was −$179.75M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by EBITDA
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation